Altogether 42% of the high-dose patients achieved a complete response, with the drug eliminating the red, scaly patches of skin on the patients afflicted by psoriasis. The positive data takes the IL-17 drug another big step toward regulators, a journey that can be completed after the companies get a look at head-to-head data against Stelara (ustekinumab)
Both companies have had high hopes for their drug (AMG827), particularly after the therapy racked up primary and secondary endpoint successes in Phase II. For Amgen it's a chance to expand its portfolio after investing heavily in its late-stage effort, while AstraZeneca has badly needed to demonstrate some pipeline successes as it tries to convince its big investors not to accept Pfizer's buyout offer.
Even if the drug looks increasingly like a winner, though, brodalumab will be up against a tough group of new rivals, all angling to divvy up a blockbuster market.
Just weeks ago Novartis pumped out more positive Phase III data for secukinumab, adding some patient satisfaction scores on the self-injected treatment. Celgene recently won an approval for Otezla for psoriatic arthritis and filed its application on psoriasis last fall. If Celgene wins at the FDA later this year, a group of analysts estimate potential peak sales of the drug will hit about $1.2 billion. Eli Lilly has an IL-17 drug as well, ixekizumab, which is in Phase III. Merck's MK-3222 is also coming along. And cheaper biosimilars of Enbrel have been pushed along by Cipla and Novartis and others.
Amgen and AstraZeneca, though, sound quite confident about their chances. Earlier this week, while laying out its case against a Pfizer megamerger, AstraZeneca assessed brodalumab's market potential at $500 million to an ambitious $1.5 billion a year, based on the analysts it listens to. But Amgen stands to gain the lion's share of the sales revenue. AstraZeneca put up $50 million in cash to partner with Amgen on brodalumab and a portfolio of anti-inflammatories back in 2012. Amgen took the lead on brodalumab, retaining commercial rights to the big U.S. market.
"Data from the AMAGINE-1 study suggest that brodalumab may offer a new level of efficacy for patients with moderate-to-
NOW IS THE TIME TO ENTER INTO THIS WONDERFUL FIELD!
With such industry leaders posting gains in profitability, they will need both certified and qualified individuals to sell their product. When industry leaders look for new candidates for entry level positions, they look toward individuals that are industry trained. Reason being that they are looking for people that have the background to sell their product both proficiently and efficiantly.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. The CNPR® represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative(